Literature DB >> 9139877

Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines.

M J Welters1, A M Fichtinger-Schepman, R A Baan, M A Hermsen, W J van der Vijgh, J Cloos, B J Braakhuis.   

Abstract

Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin show a large inter-individual variation in tumor response. Little is known about factors that contribute to this variation. The aim of our study was to correlate the sensitivity to cisplatin with a number of cellular parameters using a panel of 10 human HNSCC cell lines. A 7-fold variation in response after 72 hr of exposure to cisplatin as determined in a colorimetric proliferation assay was observed. The IC50 values did not correlate with the DNA index, the cellular doubling time or the expression of differentiation markers. Intracellular platinum (Pt) concentrations were measured by atomic absorption spectroscopy after exposing the cells to 10 microM cisplatin for 1-72 hr. The intracellular Pt levels increased up to 24 hr. One cell line, derived from the tumor of a patient previously treated with radiotherapy, accumulated much more Pt than the other cell lines. For these other cell lines, a significant positive correlation was found between Pt accumulation and sensitivity. In conclusion, cisplatin-induced growth inhibition in HNSCC in vitro is generally positively correlated with cellular Pt levels. However, the fact that occasionally cancer cells can survive despite high intracellular Pt levels indicates that additional parameters are needed to explain a response unequivocally.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139877     DOI: 10.1002/(sici)1097-0215(19970502)71:3<410::aid-ijc18>3.0.co;2-j

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

2.  Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.

Authors:  Stefan R Vink; Jan H M Schellens; Wim J van Blitterswijk; Marcel Verheij
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

3.  Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT).

Authors:  Carla F M Molthoff; Bianca M Klabbers; Johannes Berkhof; Jasper T Felten; Marcelle van Gelder; Albert D Windhorst; Ben J Slotman; Adriaan A Lammertsma
Journal:  Mol Imaging Biol       Date:  2007 Nov-Dec       Impact factor: 3.488

4.  Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET.

Authors:  Maria J W D Vosjan; Lars R Perk; Rob C Roovers; Gerard W M Visser; Marijke Stigter-van Walsum; Paul M P van Bergen En Henegouwen; Guus A M S van Dongen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

5.  Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.

Authors:  M J Welters; A M Fichtinger-Schepman; R A Baan; M J Flens; R J Scheper; B J Braakhuis
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

6.  Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.

Authors:  M J Welters; A M Fichtinger-Schepman; R A Baan; A J Jacobs-Bergmans; A Kegel; W J van der Vijgh; B J Braakhuis
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

7.  p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.

Authors:  Lars R Perk; Maria J W D Vosjan; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-18       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.